Nothing's perfect: The art of defining HLA-specific antibodies

Transplant Immunology

Volumn 30, Issue 4, 2014, Pages 115-121

  Middleton, D ^a,b   Jones, J ^a   Lowe, D ^a,b  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Clinical relevance; Crossmatch; HLA antibody; Single antigen beads; Solid phase assay

Indexed keywords

EPITOPE; HLA ANTIBODY; HLA ANTIGEN; ALLOANTIBODY; ALLOANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2;

ANTIBODY DETECTION; ANTIBODY SCREENING; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN EXPRESSION; BASE MISPAIRING; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SINGLE ANTIGEN BEAD ASSAY; EPITOPE MAPPING; GRAFT REJECTION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY;

EPITOPE MAPPING; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ISOANTIBODIES; ISOANTIGENS;

EID: 84900037366     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2014.02.003     Document Type: Review

References (37)

1. El-Awar N., Terasaki P.I., Nguyen A., Sasaki N., Morales-Buenrostro L.E., Saji H., et al. Epitopes of human leukocyte antigen class I antibodies found in sera of normal healthy males and cord blood. Hum Immunol 2009, 70(10):844-853.
2. Vlad G., Ho E.K., Vasilescu E.R., Colovai A.I., Stokes M.B., Markowitz G.S., et al. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol 2009, 70(8):589-594.
3. Billen E.V., Christiaans M.H., Lee J., van den Berg-Loonen E.M. Donor-directed HLA antibodies before and after transplantectomy detected by the Luminex single antigen assay. Transplantation 2009, 87(4):563-569.
4. Phelan D., Mohanakumar T., Ramachandran S., Jendrisak M.D. Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay. Hum Immunol 2009, 70(8):584-588.
5. Eng H.S., Bennett G., Bardy P., Coghlan P., Russ G.R., Coates P.T. Clinical significance of anti-HLA antibodies detected by Luminex: enhancing the interpretation of CDC-BXM and important post-transplantation monitoring tools. Hum Immunol 2009, 70(8):595-599.
6. Szatmary P., Jones J., Hammad A., Middleton D. Impact of sensitivity of human leucocyte antigen antibody detection by Luminex technology on graft loss at 1year. Clin Kidney J 2013, 6(3):283-286.
7. Taylor C.J., Kosmoliaptsis V., Summers D.M., Bradley J.A. Back to the future: application of contemporary technology to long-standing questions about the clinical relevance of human leukocyte antigen-specific alloantibodies in renal transplantation. Hum Immunol 2009, 70(8):563-568.
8. Warner P.R., Youngs D., Nelson K.A. 25-P: HLA density on microparticles versus antibody detection sensitivity: implications for crossmatch prediction. Hum Immunol 2007, 68(1):S28.
9. Zachary A.A., Sholander J.T., Houp J.A., Leffell M.S. Using real data for a virtual crossmatch. Hum Immunol 2009, 70(8):574-579.
10. Ramon D.S., Wagner W., Thraten D., Barabanova Y., Abdulbari R., Mandal K., et al. 41-OR: the DQ dichotomy; to V or not to V (virtual XM). Hum Immunol 2009, 70(Suppl. 1(0)):S165.
11. Reed E.F., Rao P., Zhang Z., Gebel H., Bray R.A., Guleria I., et al. Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. Am J Transplant 2013, 13(7):1859-1870.
12. Tait B.D., Susal C., Gebel H.M., Nickerson P.W., Zachary A.A., Claas F.H., et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013, 95(1):19-47.
13. MFI values don't travel: results of an inter-centre study. Transplant International 2011, Wiley-Blackwell Commerce Place, 350 Main St., Malden, 02148 MA, USA. A. Robson, J. Jones, K. Cullen, D. McKenzie, A. Wortley (Eds.).
14. Claas F.H., Doxiadis I.I. Human leukocyte antigen antibody detection and kidney allocation within Eurotransplant. Hum Immunol 2009, 70(8):636-639.
15. Gombos P., Opelz G., Scherer S., Morath C., Zeier M., Schemmer P., et al. Influence of test technique on sensitization status of patients on the kidney transplant waiting list. Am J Transplant 2013, 13(8):2075-2082.
16. Zachary A.A., Montgomery R.A., Leffell M.S. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol 2005, 66(4):364-370.
17. Morales-Buenrostro L.E., Terasaki P.I., Marino-Vazquez L.A., Lee J.H., El-Awar N., Alberu J. "Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008, 86(8):1111-1115.
18. Sicard A., Amrouche L., Suberbielle C., Carmagnat M., Candon S., Thervet E., et al. Outcome of kidney transplantations performed with preformed donor-specific antibodies of unknown etiology. Am J Transplant 2014, 14(1):193-201.
19. Crespo M., Torio A., Mas V., Redondo D., Pérez-Sáez M.J., Mir M., et al. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?. Transpl Immunol 2013, 29(1-4):28-33.
20. Zeevi A., Lunz J., Feingold B., Shullo M., Bermudez C., Teuteberg J., et al. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant 2013, 32(1):98-105.
21. Chen G., Sequeira F., Tyan D.B. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol 2011, 72(10):849-858.
22. Gebel H.M., Liwski R.S., Bray R.A. Technical aspects of HLA antibody testing. Curr Opin Organ Transplant 2013, 18(4):455-462.
23. Gloor J., Cosio F., Lager D.J., Stegall M.D. The spectrum of antibody-mediated renal allograft injury: implications for treatment. Am J Transplant 2008, 8(7):1367-1373.
24. Lowe D., Hathaway M., Briggs D. The high-dose hook effect in the detection and monitoring of HLA specific antibody by Luminex assay. Int J Immunogenet 2007, 34:288.
25. Locke J.E., Segev D.L., Warren D.S., Dominici F., Simpkins C.E., Montgomery R.A. Outcomes of kidneys from donors after cardiac death: implications for allocation and preservation. Am J Transplant 2007, 7(7):1797-1807.
26. El-Awar N., Terasaki P.I., Cai J., Deng C.T., Ozawa M., Nguyen A., et al. Epitopes of HLA-A, B, C, DR, DQ, DP and MICA antigens. Clin Transpl 2009, 295-321.
27. Zachary A.A., Vega R.M., Leffell M.S. Multiplex bead antibody assays: how do we know when HLA antibody is really there and how much of it is there?. ASHI Quarterly 2013, 37(1):18-23.
28. Susal C., Roelen D.L., Fischer G., Campos E.F., Gerbase-DeLima M., Honger G., et al. Algorithms for the determination of unacceptable HLA antigen mismatches in kidney transplant recipients. Tissue Antigens 2013, 82(2):83-92.
29. Higgins R., Lowe D., Hathaway M., Williams C., Lam F.T., Kashi H., et al. Human leukocyte antigen antibody-incompatible renal transplantation: excellent medium-term outcomes with negative cytotoxic crossmatch. Transplantation 2011, 92(8):900-906.
30. Gebel H.M., Bray R.A. In search of perfection. Am J Transplant 2013, 13(8):1951-1952.
31. Middleton D., Douglas J.F., Opelz G., Doehler B., McGeown M.G. One thousand renal transplants in Belfast. Clin Transpl 2004, 151-165.
32. Taylor C.J., Kosmoliaptsis V., Sharples L.D., Prezzi D., Morgan C.H., Key T., et al. Ten-year experience of selective omission of the pretransplant crossmatch test in deceased donor kidney transplantation. Transplantation 2010, 89(2):185-193.
33. Cecka J.M., Kucheryavaya A.Y., Reinsmoen N.L., Leffell M.S. Calculated PRA: initial results show benefits for sensitized patients and a reduction in positive crossmatches. Am J Transplant 2011, 11(4):719-724.
34. Tapiawala S., DenHollander N., Campbell P., Nickerson P., Tinckam K. 64-P: solid phase PRA (SPP) testing identifies patients whose positive initial T cell XM cannot be explained on the basis of HLA A, B, C, DR, DQ antibodies (Ab). Hum Immunol 2009, 70(Suppl. 1(0)):S42.
35. Duquesnoy R.J. A structurally based approach to determine HLA compatibility at the humoral immune level. Hum Immunol 2006, 67(11):847-862.
36. Kosmoliaptsis V., Bradley J.A., Sharples L.D., Chaudhry A., Key T., Goodman R.S., et al. Predicting the immunogenicity of human leukocyte antigen class I alloantigens using structural epitope analysis determined by HLAMatchmaker. Transplantation 2008, 85(12):1817-1825.
37. Lowe D., Shabir S., Buckels J., Muiesan P., Hayden G., Holt A., et al. HLA incompatible combined liver-kidney transplantation: dynamics of antibody modulation revealed by a novel approach to HLA antibody characterisation. Transpl Immunol 2014, 30(1):30-33.